Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.

Mahajan S, Hogan JK, Shlyakhter D, Oh L, Salituro FG, Farmer L, Hoock TC.

J Pharmacol Exp Ther. 2015 May;353(2):405-14. doi: 10.1124/jpet.114.221176. Epub 2015 Mar 11.

PMID:
25762693
2.

Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes.

Jain J, Almquist SJ, Ford PJ, Shlyakhter D, Wang Y, Nimmesgern E, Germann UA.

Biochem Pharmacol. 2004 Feb 15;67(4):767-76.

PMID:
14757177
3.

Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor.

Jain J, Almquist SJ, Heiser AD, Shlyakhter D, Leon E, Memmott C, Moody CS, Nimmesgern E, Decker C.

J Pharmacol Exp Ther. 2002 Sep;302(3):1272-7.

PMID:
12183689
4.

VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent.

Jain J, Almquist SJ, Shlyakhter D, Harding MW.

J Pharm Sci. 2001 May;90(5):625-37.

PMID:
11288107
6.

Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.

Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW.

Anticancer Drugs. 1997 Feb;8(2):125-40.

PMID:
9073309

Supplemental Content

Loading ...
Support Center